Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
Management of glioblastoma: State of the art and future directions
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
VEGF in signaling and disease: beyond discovery and development
The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our
understanding of vasculogenesis and angiogenesis during development and physiological …
understanding of vasculogenesis and angiogenesis during development and physiological …
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Immunotherapy has emerged as a major therapeutic modality in oncology. Currently,
however, the majority of patients with cancer do not derive benefit from these treatments …
however, the majority of patients with cancer do not derive benefit from these treatments …
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …
cause of morbidity and mortality. In recent years there have been important advances in …
A randomized trial of bevacizumab for newly diagnosed glioblastoma
MR Gilbert, JJ Dignam, TS Armstrong… - … England Journal of …, 2014 - Mass Medical Soc
Background Concurrent treatment with temozolomide and radiotherapy followed by
maintenance temozolomide is the standard of care for patients with newly diagnosed …
maintenance temozolomide is the standard of care for patients with newly diagnosed …
Glioblastoma and other malignant gliomas: a clinical review
A Omuro, LM DeAngelis - Jama, 2013 - jamanetwork.com
Importance Glioblastomas and malignant gliomas are the most common primary malignant
brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new …
brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new …
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
M Weller, M Van Den Bent, JC Tonn, R Stupp… - The lancet …, 2017 - thelancet.com
Summary The European Association for Neuro-Oncology guideline provides
recommendations for the clinical care of adult patients with astrocytic and oligodendroglial …
recommendations for the clinical care of adult patients with astrocytic and oligodendroglial …
Molecular targeted therapy of glioblastoma
E Le Rhun, M Preusser, P Roth, DA Reardon… - Cancer treatment …, 2019 - Elsevier
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …